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ABSTRACT 
The purpose of this study was to explore · whether lymphocyte activation and 
mononuclear cell apoptosis is dis-regulated by a diabetic situation which results in altered 
responses to bacterial infection. Based on other investigator's results NO production by 
macrophages is increased in diabetic mice therefore, the effects of NO on these processes 
are also examined. 
Diabetic (db-/db-) and background matched control (db+/db-) mice were injected with or 
without LPS. An iNOS inhibitor (AMT) was used in selected experiments. Activation of 
spleen lymphocytes and apoptosis of the mononuclear cells was examined using flow 
cytometry and ELISA. 
The results suggest that diabetes could affect lymphocyte activation and macrophage 
apoptosis. Nitric oxide may play a role in CD69 expression by diabetic T lymphocytes 
and have an opposite effect on B lymphocytes . These findings support the hypothesis that 
the kinetics and magnitude of the host response in diabetic and normal mice are different, 
which leads to an altered inflammatory course during the microbial infection . 
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Introduction 
Diabetic patients have been historically associated with an increased risk for bacterial 
infections including oral infections such as periodontal diseases (Katz et al, 1991 ). Most 
of the periodontal diseases are produced by specific Gram-negative anaerobic bacterial 
infections leading to the destruction of primarily the connective tissues and secondarily 
the underlying alveolar bone supporting the teeth. One of the Gram negative bacteria that 
have been know for producing periodontitis is Porphyromonas gingi.valis. P. gingivalis is 
thought to be an important pathogen in periodontitis and other oral infections. P. 
gingivalis colonization of subgingival sites is associated with gingival inflammation, 
spontaneous gingival bleeding with ongoing loss of periodontal attachment and crestal 
alveolar bone (Sockransky et al 1991). 
Bacteria or bacterial products such as lipopolysaccharide (LPS), fimbriae, or vesicles, 
gain access to the gingival tissue and stimulate an inflammatory response characterized 
by infiltration of neutrophils, lymphocytes, macrophages and mast cells (Haber et al, 
1991; Ogawa et al, 1991; Hanazawa et al, 1991; Graves, 1998; Rossomando et al, 1990). 
Recent epidemiologic studies have clearly reported that diabetes increases the risk of 
both severe periodontitis and the incidence of periodontal disease progression by 
approximately 2-3 fold (Haber et al, 1991; Grossi et al, 1994). An alteration in the host -
response in diabetics is thought to contribute to the enhanced risk of periodontal disease. 
Individuals with diabetes (Type I and Type 2) tend to have a higher prevalence and more 
severe progressing forms of periodontitis than non-diabetics (Cianiola et al, 1982; 
Emrich, 1991; Safkan-Seppala, 1992). Traditionally, diabetics have been considered 
more susceptible to severe periodontal disease due to metabolic and host response 
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imbalances that result in impaired wound healing, microangiopathy, and diminished 
salivary flow (Broadley et al, 1989-90; Hove; Stallard, 1970; Lamey et al, 1992). More 
recent investigations performed at the cellular/molecular level demonstrating common 
changes in systemic physiology have provided initial evidence of potential mechanisms 
responsible for the observed associations. These include diabetes-induced alterations of 
immune cell phenotype and elevation of serum proinflammatory cytokine 
(lymphocytes/monocytes/ polymorph nuclear leukocytes), lipid levels and down 
regulation of growth factors from macrophages (Pociot et al, 1993; Doxey et al, 1998; 
Iacopino, 1995; Cutler, 1999; Salvi et al, 1997; Taylor et al, 1996). 
The purpose of this study was to explore whether lymphocyte activation and 
mononuclear cell apoptosis were disrupted by a diabetic situation which resulted in 
altered responses to bacterial infection. Based on other investigators' results, NO 
production by macrophages was increased in diabetic mice therefore; the effects of NO 
on these processes were also examined. 
Literature Review 
Diabetes mellitus is a chronic disorder of carbohydrate, fat and protein metabolism. a. 
About 3% of the world's population or approximately 100 million people suffer from 
diabetes making this one of the most common noncommunicable diseases. Diabetes 
affects an estimated 16 million people in the United States. The annual mortality rate is 
about 54,000 and diabetic complications are the seventh leading cause of death (Rubin 
and Farber, 1994). 
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There are two common variants of diabetes: Type 1 and type 2. Type 1 Diabetes also 
called insulin-dependent diabetes mellitus (IDDM) accounts for about 10% of all cases of 
primary diabetes and previously referred to as juvenile-onset diabetes. Type 2 Diabetes 
formerly called non-insulin -dependent diabetes mellitus (NIDDM) and previ0t1isly 
referred to as adult-onset diabetes affects 80-90% of people (Defronzo et al, 1983 ). 
Type 2 diabetes has a powerful genetic predisposition to although the exact genetic 
basis is not known. Multifactorial inheritance is a key factor in the development of type 
2 diabetes. Sixty percent of patients have either a parent or a sibling with this disease. 
When one member of a monozygotic twin has the disease, the second twin is almost 
invariably affected (Cotran et al, 1999). 
Many patients with type 2 diabetes are asymptomatic and their diabetes is either 
diagnosed during screening for diabetes or when the patient is seen for another 
unrelated medical problem. Common symptoms are polyuria and polydipsia in patients 
who are often older (over 40 years) and frequently obese. The diagnosis is made after 
routine blood or urine testing. Patients who develop type 2 diabetes exhibit alterations 
in glucose metabolism, creating two major problems: impaired secretion of insulin by 
the beta cells and reduced uptake of insulin by peripheral cells. The person with Type 2 
diabetes suffers from impaired insulin release by the beta cell in response to glucose 
stimulation, a lesion that is most prominent in those with severe hyperglycemia. 
Despite the defect in insulin secretion by the beta cell, many patients with Type 2 
diabetes exhibit an increase in insulin concentration in the blood. This seemingly 
paradoxical situation is attributed to a reduction in the number of insulin receptors in 
the plasma membrane of adipocytes and skeletal muscle cells. 
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The insulin receptor is composed of two-linked glycoprotein subunits: B-component 
that binds insulin; and a-subunit that serves as a transmembrane protein kinase 
(tyrosine kinase). In obese patients the number of membrane insulin receptors is 
reduced. This down-regulation of insulin receptors in obesity may explain the high 
circulating insulin levels. In turn, high levels of insulin further down-regulate the 
expression of insulin receptors in fat and skeletal muscle. This mechanism is not fully 
understood. 
Although most people with Type 2 diabetes are overweight only a small proportion 
of obese people develop diabetes. Moreover, even very thin persons can have diabetes. 
Obesity contributes to Type 2 diabetes in genetically susceptible persons, but by itself is 
insufficient to produce the disease. 
Persons with diabetes are subjected to numerous secondary complications. The 
development of secondary lesions in the diabetic patient relates to the severity and 
chronicity of hyperglycemia. The morbidity associated with long-standing diabetes of 
· either type results from a number of serious complications namely microangiopathy , 
retinopathy, nephropathy, and neuropathy. In both forms of long standing diabetes, 
atherosclerotic events such as myocardial infarction, cerebrovascular accidents, gangrene 
of the leg and renal insufficiency are the most threatening and most frequent 
concomitants (Defronzo et al, 1983 ). The diabetic state is said to decrease host resistance 
to infection. Acute infection is known to alter the endocrinologic -metabolic status of the 
host (Moncada et al, 1991 ). Infections such as tuberculosis pneumonia and pyelonephritis 
cause 5% of deaths of diabetic patients. 
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Although progress has been made, the mechanisms by which diabetes exacerbate 
infection and other diseases remain unclear. 
Inflammation 
Inflammation is a fundamental pathologic process consisting of a dynamic complex of 
cytological and histological reactions that occur in the affected blood vessels and adjacent 
tissues in response to an injury or abnormal stimulation caused by a physical, chemical, 
or biologic agent. Inflammation includes: 1) local reactions and resulting morphologic 
changes, 2) the destruction or removal of the injurious material and 3) the responses that 
lead to repair and healing. It is a protective response of the body to get rid of the 
substances, the end result of injury, such as necrotic cells, tissue debris, etc. and 
infectious microorganisms such as bacteria, virus, parasites and their toxins. Acute 
inflammation has a fairly rapid onset, and usually has a clear and distinct termination. 
Clinically, acute inflammation is characterized by 5 cardinal signs of which are rubor 
(redness), calor (increased heat), and tumor (swelling), dolor (pain), and functio laesa 
(loss of function). It involves the exudation of fluid and plasma proteins and the 
emigration of leukocytes, predominantly neutrophils. Chronic inflammation may begin 
with a relatively rapid onset or in a slow, insidious, and even unnoticed manner. It may 
persist for several weeks, months or years and may have a vague and indefinite 
termination. Chronic inflammation is associated with the infiltration of T lymphocytes, 
macrophages and the proliferation of blood vessels and connective tissue as an anabolic 
response (Chandrasoma; Taylor, 1991; Gimbrone, 1992; Ryan and Majno, 1977). 
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The vascular and cellular responses of inflammatory process are triggered by 
inflammatory stimuli and mediated by factors derived from plasma or resident and 
inflammatory cells. The first change is the active vasodilatation of arterioles, capillaries 
and venules resulting in a marked increase in the amount of blood flow in the area. The 
release of histamine and bradykinin, cause increased permeability of the 
microvasculature which results from the contraction of actin filaments in endothelial 
cells, followed by the widening of intercellular space. Next, leukocytic migration starts 
and rolling and adhesion occur on the endothelial surface. These events are mediated by 
adhesion molecules on the endothelial cell surface called integrins and selectins. After 
adhesion, leukocytes move towards the junctions between endothelial cells, squeeze 
through the junctions and move into the space between endothelial cell and the basement 
membrane. Eventually they traverse the basement and migrate into the extra vascular 
space. When they reach to the site of injury, phagocytosis takes place through phagosome 
and the degradation of the particle occurs inside of the phagosome by lysosomal enzymes 
and O2-derived active metabolites (Leirisalo-Repo, 1994). 
Macrophages and Lymphocytes 
Two primary host responses discussed here are lymphocyte and macrophage function. 
There are 2 main lymphocyte populations: T cells and B cells. T cells constitute 65-80% 
of the recirculation pool of small lymphocytes and their life span is long: months or 
years. T cells arise from the stem cells in the bone marrow and they undergo maturation 
in the thymus gland. During the last stage T cells migrate from the thymus to the blood 
and lymphatic system. As T cells form they acquire surface markers: CD3, CD4 and 
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CDS. CD3 are proteins on the T cell surface in association with antigen receptors. The 
CD3 complex of 5 transmembrane proteins is involved with transmitting from the outside 
of the cell to the inside, the information that the antigen receptor is occupied. This signal 
is transmitted via several second messengers. Another important element the T cell 
receptor (TCR), is an antigen receptor isolated from a variety of T cells by 
immunoprecipitation with monoclonal antibodies that has been shown to be composed of 
an acidic a chain and a basic f3 chain (Y ague et al, 1985). 
CD4 cells are helper T cells that secrete cytokines that influence all the cells of the 
immune system including T cells, B cells, macrophages and NK cells. CD4 cells can be 
subdivided into two subunits: Thl and Th2. Thl cells are primarily involved in 
macrophage-dependent immune responses and synthesize and secrete interleukin-2 (11-2) 
and interferon-gamma (INF-y) both are involved in delayed hypersensitivity. Th2 cells 
facilitate the synthesis of other types of antibodies by B cells. They synthesize and 
secrete IL-4 and IL-5 which perform the B cell helper function. 
CDS T cells are either cytotoxic or suppressive and can inhibit the immune response 
to a specific antigen or immune cell. They kill by two mechanisms; release of perforins 
which destroy cell membrane or the induction of programmed cell death ( apoptosis) 
(Roitt et al, 1998). 
B cells are present in blood, lymphoid tissue, spleen and bone marrow and they give 
rise to antibody-producing plasma cells. They constitute 30% of the recirculating pool of 
small lymphocytes and their life span is short: days or weeks. Pre-B cells lack surface 
immunoglobulins and light chains but do have u heavy chains in the cytoplasm. The 
maturation of B cells has two phases: the antigen-dependent phase consists of stem cells, 
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pre-B cells, and B cells. The antigen -dependent phase consists of the cells that arise 
subsequent to the interaction of antigen with the B cells. B cells initially display surface 
IgM which serves as a receptor for antigens (Levinson and Jawetz, 1996). 
Activation of B cells requires two signals: the binding of antigen to the B cell's 
receptors and stimulation of the B cell by T-cell cytokines. Antigens activate both T and 
B cells, which act as functional partners in producing immunological reactivity. 
T helper cells bind to antigen on the surface of a B cell that has already bound itself to 
the antigen. The helper cell then promotes activation and maturation of the B cell. 
Antigens that can evoke an antibody response are called T-independent antigens. At 
times, these antigens can activate a large number of B cells a phenomenon known as 
polyclonal B cell activation. A number of infectious agents are capable of causing this 
activation such as Epstein-Barr virus and LPS (Roitt et al, 1998). 
NO synthesis in human lymphocytes is questionable but cytokines secreted by 
activated lymphocytes regulate NO synthesis in macrophages. T-helper -1 lymphocytes 
synthesize cytokines known to induce iNOS whereas Th-2 cells produce suppressive 
signals for iNOS in murine macrophages (Moncada 1992 et Langrehr 1993). Futhermore 
NO synthesized by the activated macrophages can inhibit the secretion of cytokines by 
Th-1 cell but has no effect on cytokine production by Th-2 cells (Taylor-Robinson, 
1994). Thus NO may serve as a mediator of the negative feedback regulation of the 
lymphocyte mediated immune response aiming to avoid over-shots of the reaction. This 
idea is supported by the in vitro data that in a co-culture of macrophages and T 
lymphocytes stimulated with Staphylococcal products the activated T lymphocytes 
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produced cytokines which induce NO synthesis in macrophages and this NO in turn 
inhibits T-lymphocyte proliferation (lsobe, 1992). 
Macrophages arise from myeloid precursors. Macrophages have two important 
functions: phagocytosis, and cytokine productioa They do not pass through the thymus 
and do not have an antigen receptor. On their surface, they bear class 2 MHC proteins 
which play an essential role in antigen presentation to helper T cells. 
The first main function is phagocytosis. Macrophages ingest bacteria, · viruses, 
apoptotic bodies, cellular debris and other foreign particles. They have surface F c 
receptors that interact with the Fe portion of immunoglobulin, thereby enhancing the 
uptake of opsonized organisms. 
The second function is cytokine production where the macrophages produce numerous 
cytokines; three important inflammatory cytokines are IL-la, IL-1~, TNFa. 
Local Effects of Periodontitis and Inflqmmatioq: 
Much of periodontal tissue destruction observed in periodontitis is host mediated 
through release of proinflammatory cytokines by local tissues and immune cells in 
response to the bacterial flora and its products/ metabolites, especially LPS 
(lipopolysaccharide) (Socransky, 1992). 
Two major proinflammatory cytokines implicated in the progression of periodontal 
disease are TNFa and IL-1. Both IL-1 and TNF induce several events associated with 
jnflammation and tissue destruction (Dinarello, 1996, Bazzoni, 1996, Ridderstad, 1991 ). 
They induce up regulation of adhesion molecules in leukocytes and endothelial cells, 
leading to enhanced migration from the vascular lumen into interstitial connective tissue. 
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Il.,-1 and TNF can also induce expression of chemo tactic mediators, stimulate the 
production of lytic enzymes in a variety of cell types and enhance phagocytic activity and 
osteoclast formation. For many of these activities, Il.,-1 and TNF are synergistic (Graves, 
1998). In diabetic patients they found significantly higher levels of TNFa in 
gingival crevicular fluid, compared to non-diabetic controls matched for periodontal 
disease severity. This · may be explained by in vitro findings that peripheral blood 
monocytes from diabetic individuals produce significantly more 1NFa than individuals 
without diabetes (Salvi et al 1998). Thus diabetics may over produce TNF- which 
increases the risk for bone resorption and loss of periodontal attachment. In primate 
model of experimental periodontitis, application of antagonists to IL-I and TNF resulted 
in an 80 % reduction in recruitment of inflammatory cells in proximity to the alveolar 
bone and a 60% reduction in bone loss (Assuma R et el, 1998). 
Diabete~ tu1dPeriotlontal Inflammation 
It is generally accepted that there is an association between diabetes and periodontitis. 
Periodontitis is a chronic inflammation represented primarily 
by anaerobic Gram-negative oral infection leading to gingival inflammation, destruction 
of periodontal tissues ·and loss of alveolar bone and exfoliation of teeth in severe cases 
(Iacopino and Anthony, 2001 ). 
Porphyromonas gingivalis is an obligately anaerobic non-motile, gram-negative rod 
and it is thought to be an important pathogen in periodontitis. It colonizes sub gingival 
sites and causes gingival inflammation, spontaneous gingival bleeding with ongoing loss 
of periodontal attachment and crestal alveolar bone (Male et al, 1994). 
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P. gingivalis possesses several virulence factors that are likely to define its interaction 
with host cells. These include production of fimhriae, hemagglutinating factors, LPS and 
its polysaccharide capsule. P gingivalis funbriae and LPS play a major role. Fimbrias 
(pill) are proteinaceous, filamentous, and nonflagella appendages which project outwards 
from the bacterial cell surface and often play an important role in virulence by facilitating 
bacterial attachment to host cells (Njoroge et al, 1997). P. gingivalis pathogenicity has 
the ability to adhere to tooth surfaces and invade sulcular epithelium. Its fimbriae play a 
central role in both processes. 
The outer leaflet of Gram negative bacteria contains lipopolysaccharide. (LPS) LPS is 
a compound or complex of lipid and carbohydrate. P gingivalis (LPS) induces a number 
of inflammatory mediators including PGE2, IL- I and IL-8 (Darveau et al, 2000). 
Recent investigations concerning the relationship between diabetes and periodontitis 
show alterations of immune cell phenotype and elevation of serum proinflammatory 
cytokine/lipid levels (Pociot et al, 1993, Salvi et al, 1997, Doxey et al, 1998, Iacopino, 
1995, Cutler et al, 1999). Most recent studies have demonstrated that periodontitis itself 
can produce these same alterations and in the presence of diabetes produces exacerbation 
of these changes (Cutler et al, 1999, Prabhu et al, 1996, Salvi et al, 1998, Ebersole et al, 
1999, Iacopino et al, 2000). 
Microscopic examination of tissue specimens collected from patients with periodontal 
disease indicates that normal tissue architecture is altered in association with the 
accumulation of T and B lymphocytes, plasma cells and the presence of large numbers of 
PMN in the junctional and sulcular epithelium and gingival crevice (Page and Schroeder, 
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1976). Abnormalities in host defense mechanisms account for an increase frequency of 
certain types of infection in diabetic patients (Darveau et al, 2000).} 
Nitr!c (Jxide Production and Function 
Nitric Oxide (NO) has multiple and divergent roles in various systems and tissues. 
Nitric oxide (NO), a free radical gas is a noxious chemical in the atmosphere but in small 
controlled concentrations in the body it acts as a physiological and pathophysiologicaI 
mediator (Moncada et al, 1991; Lincoln et al, 1997). Generated by many cell types in a 
variety of tissues, it acts as a vascular relaxing agent, a neurotransmitter and an inhibitor 
of platelet aggregation. In addition to these physiological roles, NO is generated during 
immune and inflammatory responses, where its function is less well defined and more 
complex (Moncada et al, 1991; Nathan et al; Xie, 1994). It may also act as an anti-
inflammatory or immunosuppressive agent via its inhibitory or apoptotic effects on 
leukocytes. (Coleman, 2001) 
NO also has a role in the pathogenesis of certain diseases such as atherosclerosis, 
insulin-dependent diabetes mellitus and arthritis. It has been established that inducible 
nitric oxide synthase (iNOS) can be stimulated in certain cell types by proinflammatory 
cytokines such as interferon-y (IFNy), tumor necrosis factor-a (TNFa) and interleukin-I~ 
(IL-1 ~) resulting in significant amounts of nitric oxide production (Nathan et Xie, 1994). 
In most cases, in mammalian cells, NO is produced through the L-arginine/ nitric 
oxide synthase pathway. An important intermediate step in this reaction is the fonnation 
ofN-hydroxy-L-arginine (NOHA) which is further oxidized to L-citrulline by NOS with 
NADPH and 02 as cofactors. NOHA can be converted to NO and L-citrulline through 
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the catalytic action of certain hemeproteins as well as cytochrome P450-dependent 
monooxygenases from mouse liver microsomes (Champe & Harvey, 1994). 
Two major forms of NOS activity were initially described: one that is constitutively 
expressed ( cNOS) and is regulated by Ca/calmodulin, and produces small amounts of NO 
for short periods of time upon stimulation (Moncada et al, 1991). The second is 
inducible (iNOS) which requires de novo synthesis and is not dependent on Ca 
regulation. Induction of iNOS in most tissues and cell types is initiated by cytokines and-
/or lipopolysaccbaride (LPS). Once expressed, the enzyme produces large amounts of 
nitric oxide for the duration of the active enzyme, which could be over 48 hours (Liew, 
Moss, Parkinson, Rogers and Moncada, 1991 ). 
Three isoforms. ofNOS have been characterized: the constitutive neuronal NOS/type 
I, the constitutive endothelial NOS/type Ill and the inducible macrophage NO$/type II 
. . - . ·:,--. 
(Alderton and Cooper and Knowles, 2001 ). 
The constitutive NOS was found in the vascular endothelium, the central and 
peripheral nervous system, the retina, neuroblastoma cells, cardiac myocytes and 
endocardial cells, kidney epithelial and mesangial cells, bronchia epithelial cells, 
pancreatic B cell, adrenal medullary cells, megakaryoblastic cells~ platelets and mast cells 
(Moncada et al, 1991; Snyder et al 1993). It is activated in response to a calcium signal 
generated for example by the arrival of an action potential at a nerve ending, or activation 
of endothelial cell receptors by acetylcholine. Enzyme activation occurs rapidly and 
transiently, according to the kinetics of the calcium signal. Production of NO is equally 
transient, providing a rapid pulse-like signal to the responding cell ( e.g. neuron or smooth 
muscle cell) (Moncada et al, 1991; Lincoln et al, 1997). 
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iNOS is the isoform involved in the immune response. Several cell types including 
macrophages, chondrocytes, neutrophils, endothelial cells, hepatocytes and smooth 
muscle cells have been reported to express iNOS in response to inflammatory stimuli but 
interspecies differences seem to occur. 
Macrophages have also been reported to express NOS activity through alternative 
activation pathways, not necessarily involving cytokine stimulation. Murine and hwnan 
macrophages produce NO after phagocytosis of microorganisms (Langrehr, 1993). The 
antimicrobial and cytotoxic actions of NO are enhanced by other macrophage products 
such as acid, glutathione, cysteine, hydrogen peroxide, or super oxide (MacMicking et al, 
1997. 
Macrophage Dysfunction qs a Diabetic Complication,. . 
• ~-. •• --~- :;...;r~v~• -. -,!:,O• 0 
Zykova et al, 2000 concluded that macrophage dysfunction is a likely mechanism 
underlying common diabetic complications such, as increased susceptibility to infection, 
accelerated atherosclerosis, and disturbed wound healing. He investigated macrophages 
in a murine model of type 2 diabetes and found that they release more NO when 
stimulated by LPS and less of the typical macrophage cytokines (INF-a and IL-lf3) and 
VEGF upon stimulation in vitro than the cells from phenotypically nonnal mice of the 
same strain. Various reactive oxygen and nitrogen species released by activated 
macrophages have been postulated to exert strong cytotoxic and bactericidic effects 
which could even affect the metabolic activity and vitality of the macrophages 
themselves (Drapler and Hibbs, 1988) Zykova did not know if this is related to the 
decrease in macrophage functions as seen by the decreased release of cytokines. 
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Several reports indicate up regulation of the iNOS pathway in the diabetic state 
(Stevens et al, 1997). Nitrite/nitrate accumulation in wound fluid of streptozotocin-
induced diabetic rats was significantly diminished (Schaffer, 1997). AGE (Advanced 
glycation end products) which form as a consequence of long-standing hyperglycemia, 
accumulate in macrophages and may compromise normal cellular functioning, quench 
NO in tissues decreasing amounts of free NO in situ and consequently hyperproduction 
ofNO by macrophages (Zykova, 2000). 
iNOS Inhibitors 
Unfortunately, the literature on NOS inhibitors has many misleading statements and 
claims about the selectivity of many of these inhibitors. This has been a consequence of 
differing criteria for what constitutes selectivity and how selectivity is defined. Inhibitors 
with less than 10-fold selectivity are unlikely to be useful as selective agents because of 
the difficulties inherent in attempting to use them in such a way that only one isoform is 
affected and they are regarded as non-selective. Inhibitors with compounds of over 50 or 
l 00-fold selectivity become much simpler to use to inhibit the activity of a single isoform 
without affecting others and also start to have potential as selective therapeutic agents 
without the potential for side effects that might arise from inhibiting the other isoforms 
(Alderton et al, 2001). 
A variety of arginine analogs which act as NOS specific inhibitors have been 
described (Knowles et al, 2001 ). These analogs are stereoselective, and include NG-
monomethyl-L-arginine (L-NMMA), NG-nitro-L-arginine (L-NNA), NG-nitro-L-
arginine methyl ester (L-NAME), NG-amino-L-arginine (L-NAA), N-ethylimino-L-
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ornithine (L-NIO). Various studies have shown cell and isoform selectivity for these 
compounds: L-NNA seems to be much less potent in inhibiting the iNOS than the cNOS 
isoform. L-NAA and L-NNA are about 100-fold more potent than L-NMMA in blocking 
endothelial NO synthesis. L-NIO was found to be the most potent selective inhibitor of 
rat neutrophil and murine macrophage iNOS when compared to L-NMMA. 
The three NOS isozymes produce NO in separate tissues for different purposes in both 
normal and diseased states, and selective inhibition of the appropriate isozyme could 
avoid complications in the treatment of a diseased state. NOS inhibitors are known to 
increase blood pressure and have been used to reverse the hypotension observed in septic 
shock. (Moncada et al, 991 ). Selective type II nitric oxide synthase inhibitors have 
several potential therapeutic applications, including treatment of sepsis, diabetes, and 
autoimmune diseases (Tracey and Nakane and Basha and Carter, 1995). 
It seems clear that for the treatment of the above-mentioned pathophysiologies a selective 
inhibition of the inducible isoform is absolutely necessary and the nonselective inhibitors 
will deteriorate these conditions due to concomitant inhibition of constitutive isoforms 
(Boer et al, 2000). Most inhibitors identified so far are competitive with the substate L· 
arginine and have therefore been inferred to be binding at the arginine -binding site 
preventing NO synthase from converting L-Arginine to L-Citrulline. 
Two other recently discovered selective iNOS inhibitors EIT (s-ethylisothiourea) 
and AMT (2-amino-5, 6-dihydro-.6methyl-4H-l, 3 thiazine) are two inhibitors that are 
used for Type II NOS (Tracey, 1995). In an in vivo experiment studying 
Iipopolysaccgaride (LPS) treated rats, type II NOS activity was assessed measuring 
changes in plasma nitrite and nitrate concentrations. EIT and AMT were found to be 
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selective inhibitors of type II NOS in vitro and demonstrated a 20-fold selectivity versus 
· the type I NOS as well as a 40-fold selectivity versus the type III NOS: Both are 
reversible and competitive against L-arginine of NOS. They also represented an 85-170-
fold increase in potency in vivo. The administration of LPS and either NOS inhibitor 
resulted in a dose-dependent increase in animal mortality neither compound was lethal 
when administered alone (Tracey and Nakane and Basha and Carter, 1995). In our study 
we used the AMT inhibitor because of its high specificity, high potency . and high purity 
(98%). AMT is also well tolerated by murines. 
Apoptosis 
Apoptosis is the process of programmed cell death, where cells are deliberately killed 
as a part of physiological processes (Wyllie et al, 1997). The end result of apoptosis is 
that the cell's DNA is broken down to 200 base pair fragments. Apoptotic cells are 
recognized by phagocytes, which usually clear the cell remains without stimulating 
inflammation (Nairn and Helbert, 1999). It usually occurs during development, as a 
homeostatic mechanism to maintain cell populations in tissues, as a defense mechanism 
such as in immwie reactions when cells are damaged by disease or noxious agents, and in 
aging. The cellular events associated with apoptosis are well characterized; cell 
shrinkage, chromatin condensation, and formation of cytoplasmic blebs and apoptotic 
bodies. 
Apoptosis plays a central role in the development and regulation of the immune 
system. Apoptosis of activated T and B cells limits an immwie response after the antigen 
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has been eliminated and also plays a role in deletion of self-reactive immune cells and in 
cytotoxic killing (Ekert & Vaux, 1997). 
Programmed cell death is recognized as playing a major role in the inflammatory 
process and aberrant regulation is considered to contribute to autoimmune disorders such 
as systemic lupus erythematosis and rheumatoid arthritis, viral diseases including AIDS 
and bacterial infections aggravated by diabetes. It is apparent that microorganisms have 
developed the ability to subvert the molecular mechanisms which regulate apoptosis in 
the immune system, thereby promoting infection, inflammation and concomitant disease 
(Chen, 1994 and Zychlinsky, 1997). For example, killing cells of the immune system 
may be an advantage for the survival of pathogenic bacteria and there is now clear 
evidence that several different bacterial species have developed mechanisms to induce 
apoptosis in mammalian cells (Chen, 1994 and Liles, 1997 and Zychlinsky, 1997). 
Host cell apoptosis induced by bacteria can contribute to disease pathogenicity 
(Zychlinsky and Sansonetti, 1997) and in this regard Shigella strains have been shown to 
induce apoptosis of macrophages which may play a crucial role in disease progression 
(Guichon and Zychlinsky, 1997). 
Other experiments in mice have demonstrated that a recombinant form of the heat-
labile enterotoxin subunit B derived from Escherichia coli can induce apoptosis in murine 
CD4 and CD8 cells, although the level was higher in the latter subset (Truitt et al, 1998). 
Lipopolysaccharide from gram-negative bacteria not only activated all B cells but 
induced massive T-cell apoptosis, which may have consequences in endotoxin shock 
(Castro et al, 1998). 
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Recently P. gingivalis lipopolysaccharide administration to mice was shown to induce 
apoptosis of lymphocytes in the spleen, lymph nodes and thymus. It also showed a 
reduction in the number of splenic T cells in mice caused by apoptosis (Isogai et al, 
1996). Studies have demonstrated the presence ofapoptotic cells in P. gingivalis•specific 
T-cell lines during the first 72h after restimulation using Epstein-Barr virus-transformed 
B cells as antigen-presenting cells (Gemmell, E. 1999). Interestingly LPS from a P. 
gingivalis strain 381 appears to be more effective in inducing apoptosis in mature, splenic 
T cells compared to Escherichia coli LPS but probably exerts this effect indirectly via the 
stimulation of monocyte TNF-a (Isogai et al, 1996, Norimatsu et al, 1995). 
NO regulates death of immune cells, either through induction or inhibition of 
apoptosis or by necrosis. NO can mediate killing of tissue -specific cells in 
immunologically mediated diseases. For example NO production by macrophage iNOS 
is responsible for the killing of B-islet cells in a rodent model of autoimmune diabetes 
(Fehsel et al, 1995). These cells enter into the early stages of apoptosis, but subsequent 
energy and ATP depletion of the cells by NO switches the cells to necrotic cell death 
(Kroncke et al, 2001; Fehsel, 1995). NO regulates death ofimmune cells in vivo. In the 
mouse thymus, production of iNOS-dependent NO leads to apoptotic cell death oi an 
immature sub-population of thymic T lymphocytes, whereas a second mature subset is 
rendered resistant by NO to dexamethasone-induced apoptosis (Fehsel et al, 1995). 
In general, low concentrations of NO appear to be anti-apoptotic whereas higher 
concentrations induce cell death either by apoptosis or necrosis. At higher or sustained 
concentrations of NO the switch from apoptosis to necrosis may reflect depletion of 
cellular energy (Kroncke et al, 2001; Febsel, 1995). Whether NO induces or inhibits 
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apoptosis is also highly dependent on cell type. For example macrophages, pancreatic 
cells and thymocytes are highly susceptible to NO-induced apoptosis whereas some cells 
such as cardiac and skeletal muscle fibers and CNS neurons last a lifetime. 
The molecular events involved in signaling and regulation of lymphocyte apoptosis 
are the subject of intense research, given the wide-ranging biological importance of this 
process, but are also fuelled by the promise that therapeutic manipulation of apoptosis 
may be of benefit in diseases in which the process features in pathogenesis including 
chronic inflammatory diseases (Wong, 1997 and Anderson, 1996). 
Materigl~ andMethods 
Bacteria 
The Biological Core of (C. Genco, Pl) a Program Project headed by Dr Salamon Amar 
provided all oral bacteria. The porphyromonas gingivalis (Pg-strain 381) were cultured 
on agarose plates under strictly anaerobic conditions ( carbon dioxide and nitrogen) for 4-
5 days. The bacteria were killed by formalin the amount was quantified with a 
spectrophotometer according to ,an established standard curve. 
AMT 
AMT (2-amino-5, 6-dihydro-6methyl-4H-1) was purchased at Sigma-Aldrich. The half 
life of AMT is 12 hours. It is a selective inhibitor used for iNOS inhibition. The dosage 
of AMT was calculated based on individual mouse body weight. (Mouse weight x 
4mg/kg=AMT dose/injection) . 
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Animals 
A group of 25 diabetic (db-/db-) and 25 non-diabetic (db+/db-) mice were purchased at 
Jackson Laboratories in Bar Harbor Maine. They were 8 weeks old at the time of their 
arrival and the groups were kept in separate cages until db-/db-mice became diabetic. 
Glucose levels were checked with an Advantage glucomonitor Accu-check (Roche 
Indianapolis IN). The criteria for being diabetic are for glucose levels to go above 
250mg/dL. During the first week the glucose level was checked twice and once during 
the second week Usually the checks were done in the morning around 9:00am. 
Experiments are done at least two weeks after the mice become diabetic. One day before 
the experiment the mice were divided into 8 major groups: DAY 0: 1) control-PBS 2) 
control-AMT (Sigma Aldrich) 3) Diabetic-PBS 4) Diabetic-AMT. DAYJ: 1) control-PBS 
2) control-AMT 3) Diabetic-PBS 4) Diabetic-AMT 
Four groups were injected twice with AMT interperitoneally, (the amount of AMT 
injected was calculated based on individual mouse body weight) and four groups were 
injected with PBS interperitoneally, (amount of PBS was injected based on vehicle 
volume). The mice were anesthetized (the anesthetic contained 1.0ml Ketamine 
(lO0mg/ml) + 1.0ml Xylazine (20mg/ml) + 6.0ml PBS (lx)) and their scalps were shaved 
with electric shaver. Each mouse in the Day 3 group (all control and diabetic) was 
injected with 50ul of 5XtOA8rnl of Pg bacteria. Next day the Day 0 group was sacrificed. 
Day 3: group of mice were injected with AMT or PBS 2X every 24 hours. 72 hours after 
bacteria inoculation mice were sacrificed. 
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Cell Cuturing 
The following protocol was used for the isolation of the spleen and splenocytes: 
1. Anesthetize mice with 0.1~0.15ml of anesthetic each. 
2. Prepare and disinfect the surgical field (LUQ abdomen) with 75% alcohol. 
3. Carefully cut through the abdomen skin and peritoneum. Dissect tissue to expose 
spleen which is a long, thin, dark-red organ on the left side. 
4. Remove the spleen and transfer it to 6ml RPMI 1640(5%FBS) in a 15 ml tube on ice. 
5. Pour the content onto the mesh in the Petri-dish. 
6. Transfer only the mesh with spleen on it to another Petri-dish, which is with 4--6ml 
RPMI 1640 
7. Grind the spleen over the mesh with a syringe plunger. 
8. Collect the ground tissue to another 15ml tube. 
9. Spin for 5 minutes at 1000RPM. Discard the supernatant. 
10. Resuspend the pellet with 4ml Ammonium Chloride (Sigma A-0171) for 1 minute to 
lyse RBC. 
11. Add in 10 ml RPMI (5%FBS) to stop the lyses. 
12. Spin for 5 minutes at 1000RPM. Discard the supernatant. 
13. Resuspend the pellet with 8ml RPMI 1640(5%FBS). 
14. Underlay with 4ml Histopaque.(Sigma Diagnostics) 
15. Spin for 15 minutes at 2000 RPM 
16. There will be 3 layers in the tube now, from top to bottom, red (RPMil 640, 5%FBS), 
Cloudy and transparent (Histopaque ). 
17. Collect and transfer only the cloudy layer to another 15 ml tube. 
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18. Add in 10ml RPMI 1640(5%FBS) to wash the cells. 
19. Spin for 5 minutes at 1000 RPM. Discard the supernatant 
20. Resuspend the pellet with your desired cell culture medium 
21. Dilute then count l 5ul cell suspension onto Hemacytometer (Fisher Scientific) 
22. Count cells in shaded areas under inverted microscope 
23. Calculate the concentration by the following formula: 
(Total shaded-area cell amount/4)X 10/\4X dilution factor= cell concentration/ml 
24. Plate the cells onto a cell culture plate as your experiment design. 
Resident Peritoneal Cells 
The following protocol was used to extract peritoneal cells. 
1. Anesthetize the mice with 0. l ,_,0.15ml anesthetic each. 
2. Prepare and disinfect the surgical field with 75% alcohol the middle abdomen. 
3. Inject 10ml RMPI1640 (5%FBS) into peritoneal cavity. 
4. Using a 10ml syringe, slowly and carefully withdraw to remove the peritoneal cells. 
5. Spin for 7 minutes at 1000RPM. Discard the supernatant. 
6. Resuspend the pellet with 4ml Ammonium Chloride for 1 minute to lyse RBC. 
7. Add in 10ml RPMI (5%FBS) to stop the lyses. 
8. Spin for 7 minutes at 1000RPM. Discard the supernatant. 
9. Resuspend the pellet with your desired cell culture medium. 
10. Take I Sul cell suspension onto Hemacytometer. 
11. Count cells and calculate the concentration. 
12. Plate the cells as your experiment design. 
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Flow Cvtometrv Protocol 
Splenocyte concentration needed per well (96-well plate) is 1.5xl0A6cells/well. 
1. Plate each sample into 4 wells in a 96-well plate: 
2. CD3+CD69 
3. Rat lgG2b-PE + Hamster IgG 1-FITC. 
4. CD19+CD69 
5.~ Rat IgG2a-PE+Hamster IgGl-FITC. 
6. Incubate cells in 1 00ul blocking medium ( a- MEM containing 5% bovine serum for 
20 minutes on ice to reduce non-specific binding of antibody. 
7. Wait for 10 minutes on ice. 
8. Add 1.Sug/1 0A6 cells PE or FITC conjugated antibodies (CD3+CD69 or 
CD 19+CD69) or control lgG in each subgroup. 
9. Wait for 30 minutes on ice. 
10. Rinse twice with PBS. 
11. Fix cells in 1 % paraformaldehyde and keep in dark (wrapped in tin foil) at 4C. 
12. Analyze the samples ASAP within 1 week. 
Flowcytometer analysis was performed and data analysis was carried out with a 
F ACSCAN machine (Becton Dickinson). Number of positive cells was determined 
based on control IgG staining. For each immunofluorescent analysis approximately 
10,000 cells were examined. 
Reagents 
CD3 antibody (Becton Dickinson) identifies T lymphocytes and recognizes the epsilon 
chain of the CD3 antigenff cell antigen receptor (TCR) complex. CD 19 antibody 
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identifies B lymphocytes and recognizes a 90-kDa antigen that is present on human B 
lymphocytes at all stages of maturation but is lost on plasma cells. The CD 19 antigen 
might be involved in activation and proliferation of B lymphocytes (Knowles, 1986). 
CD69 (Becton Dickinson) is expressed on early stage of activated lymphocytes 
representing a generic marker to monitor individual subset responses to provocative 
stimuli (Testi et al, 1994). 
Cell Death Detection ELISA 
Apoptosis was measured with a photometric enzyme-immunoassay (Roche) used for the 
qualitative and quantitative in vitro determination of cytoplasm histone-associated-DNA-
fragmertts [ mono-and oligonucleosomes J after induced cell death (Darzynkfowicz et al, 
1992). 
The assay was performed using the manufacturer's following instructions: 
1. Incubated cells harvested from previous day are centrifuged, supemateq.t removed 
and lysis buffer is added. 
2. Cells are kept in room temperature for 30 minutes, and later centrifuged. 
3. Supematants containing DNA-fragments are placed into an AB-coated Elisa plate 
(Roche) with Immunoreagent, covered with adhesive cover foil and put on shaker for 
2 hours. 
4. Solution is removed and rinsed 3 xs with Incubation buffer. 
5. ABTS (2, 2'-Azino-di [3-ethylbenzthiazoline sulfonate (6)] diammonium salt 
crystals) reagent is added and cells are incubated on plate shaker at 25 0 rpm until 
color development is sufficient for a photometric analysis. 
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6. They are measured at 405nm against ABTS solution as blank [reference wavelength 
approc.490nm]. 
Results 
In our preliminary study using flow cytometry we evaluated the expression of an early 
activation marker, CD69 in spleen lymphocytes from the diabetic and nondiabetic mice. 
Based on our findings the number of CD69 positive lymphocytes was higher in diabetic 
mice compared to non-diabetic controls without bacterial injection (fig. 1). One day after 
bacterial injection the number of CD69 positive lymphocytes increased in the normal but 
not diabetic mice (fig. 2). At day 3, there is a decrease in CD 69 expression in all cells 
except normal T-cells (Fig 3). 
In order to determine the role of NO in diabetic inflammation, preliminary studies were 
undertaken using flow cytometry to evaluate the effect of NO inhibitor (AMT) on CD 69 
expression by lymphocytes from the diabetic and nondiabetic mice (Figs 4-7). The mice 
were injected with (Day 3) or without P. gingivalis (Day 0) and with or without AMT. 
The animals were sacrificed and splenocytes isolated at Day O or day 3. Consistently the 
number of CD69 positive T and B lymphocytes from the non-treated group is higher in 
the diabetic compared to the control mice ( fig 4&5). AMT slightly reduced CD 69 
expression of diabetic T cells but had no effect on non ... diabetic T cells at 0-time point (fig 
4). Surprisingly, AMT seems to increase CD69 expression on B cells of O time point 
diabetic and control mice (fig 5). 
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At Day 3 after P .g. injection, similar with the day O results, AMT has no effect on 
non-diabetic T cells but reduces CD 69 expression on diabetic T cells by 60% (fig6). The 
reverse effect of AMT on B cells becomes even more obvious. AMT increased 3 fold of 
CD69 expression ofnondiabetic B cells and 2 fold of diabetic B cells (fig 7). 
The experiments were conducted to determine the rate of apoptosis of the peritoneal 
macrophages and splenocytes between the control and diabetic mice with and without 
injection of P. gingivalis. On Day O there was a significant difference in the rate of 
apoptosis in the peritoneal macrophages between the diabetic mouse and the control 
mouse (p<0.05). The rate for the diabetic mouse was 30% higher compared to the control 
mouse (fig8). On Day 1 the rate of apoptosis is 50% higher for the diabetic compared to 
the control mouse (p<0.05) (fig9). Day 3 there is no significant difference in the rate of 
apoptosis between the control and diabetic mouse ( fig 10). 
Similar studies have been conducted on spleen lymphocytes. Although slightly lower 
apoptosis rate has been found in diabetic lymphocytes at day O and day 1, but there is no 
statistical significance. Bigger sample size might be required to detect this small 
difference if there is any. 
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Figure 1: In the preliminary study using flow cytometry the number of CD69 
positive splenocytes in control and diabetic mice was determined at Day O after 
stimulation with P.g. (»=Diabetic, N=Non-diabetic). 
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Figure 2: In the preliminary study using flow cytometry the number of CD69 
positive splenocytes in control and diabetic mice was determined at Day 1 after 
stimulation with P.g. (D=Diabetic, N=Non-diabetic). 
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Figure 3: In the preliminary study using flow cytometry the number of CD69 
positive splenocytes in control and diabetic mice was determined at Day 3 after 
stimulation with P.g. (»=Diabetic, N=Non-diabetic). 
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Fig 4: In the preliminary study, the percentage of CD 69/CD3 T lymphocytes at Day 0 
was determined using flow cytometry in control and diabetic mice after injection with 
and without NO inhibitor (AMT). 
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Fig 5: In the preliminary study, the percentage of CD 69/CD 19 B lymphocytes at Day 
0 was determined using flow cytometry 
In control and diabetic mice after injection with and without NO inhibitor (AMT) . 
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Fig 6: In the preliminary study, the percentage of CD 69/CD3 T lymphocytes at Day 3 
was determined using flow cytometry 
In control and diabetic mice after injection of P. Gingivalis and injection with and 
without NO inhibitor (AMT). 
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Fig 7: In the preliminary study, the percentage of CD 69/CD19 B lymphocytes at Day 3 
was determined using flow cytometry 
In control and diabetic mice after injection of P. Gingivalis and injection with and 
without NO inhibitor (AMT). 
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Figure 8: With optical densitometry the amount of apoptosis was determined in control 
(blue) and diabetic (red) peritoneal macrophages at Day 0. There was a significant 
difference with the rate of apoptosis being higher for the diabetic mouse as indicated by 
student t- test (p<0.05). 
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Figure 9: Using optical densitometry the amount of apoptosis was determined in control 
(blue) and diabetic (red) peritoneal macrophages I day after injection of P. gingivalis. 
There was a significant difference with the rate of apoptosis being higher for the diabetic 
as indicated by the student T-test (p<0 .05). 
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Figure 10: Using optical densitometry the amount of apoptosis was determined in control 
(blue) and diabetic mouse (red) peritoneal macrophages 3 days after injection of 
P.gingivalis. There was no significant difference as indicated by the student t-test 
(p>0.05). 
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Figure 11: Using optical densitometry the amount of apoptosis was determined in control 
(blue) and diabetic mouse (red) splenocytes at Day 0. There was no significant difference 
according to the T-test indication. 
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Figure 12: Using optical densitometry the amount of apoptosis was determined in control 
(blue) and diabetic (red) mouse splenocytes 1 day after injection of P.gingivalis. T-test 
determined no significant difference . 
35 
Splenocyte Apoptosis 
0.6 ---------------------, 
0.5 -·- --------~ =------
C) 
c: 0 4 -1--- --- - -- - - - - - ----1 :s . 
cu ~ 0.3 -
§ 0.2 ----
0.1 -t----
o --- -
3 
Days 
■ Contorol 
■ db/db 
Figure 13: Using optical densitometry the amount of apoptosis was determined in control · 
(blue) and diabetic (red) mouse splenocytes 3 days after injection of P. gingivalis . T-test 
determined no significant difference. 
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Discussion 
Infections in diabetics have been shown to persist longer than those in nondiabetics. 
This maybe due to a diminished host defense which has been shown to occur on several 
levels such as chemo taxis, phagocytosis, super oxide generation and killing of bacteria 
by phagocytes. Cutler et al, 1991 showed th~t superoxide production was enhanced in the 
IDDM PMNs suggesting IDDM PMNs are in a "primed" state. It is conceivable that with 
primed PMNs the respiratory burst occurs prior to the normal triggering of respiratory 
burst accompanying phagocytosis of particulate matter, leading to ineffectual intracellular 
killing of bacteria. Inappropriate PMN activation of this sort is also known to damage 
host cells and their genomes as well. The Gingival inflammation initiated by 
accumulation of bacteria on the tooth surface is an example of a chronic inflammatory 
process . It is contained in the gingival tissue. When this bacteria-induced inflammatory 
process reaches the periodontium, gingivitis progresses to periodontitis which leads to the 
destruction of the connective tissue including periodontal ligament and alveolar bone 
(Socransky, and Haffajee, 1991; Page, 1991, Schluger et al, 1990). 
In our study we proposed one of the mechanisms that can cause higher periodontal 
disease in diabetic patient is change in the level of activation of lymphocytes. CD69 is 
involved in the cell activation process, because some of the anti CD69 antibodies have 
been reported as able to synergize with phorbol esters in inducing a mitogenic effect on 
T, B thymocytes . The induced CD69 statement associated with inflammatory processes 
appears to be induced by proinflammatory cytokines. Up regulation of CD69 is thus 
observed in vitro after incubation of T lymphocytes with exogenous cytokines. CD69 
induces an increase in intracellular Ca, the synthesis of cytokines and their receptors, and 
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increase in cellular proliferation (Risso et al, 1989). To investigate the effect of diabetics 
on activation of lymphocytes, we first studied the difference between the number of CD 
69 expression on T cells and B cells in diabetic mice and control mice at zero time point 
using flow cytometry (fig 1). The surface markers we used for our studies were CD 3 
representing T Lymphocytes and CD 19 representing B lymphocytes. CD 69 is 
considered an early activation marker that is expressed in leukocytes during activation. 
Naive T cells and B cells after they have been activated present CD69. The number of 
CD 69 positive T cells and B cells were significantly higher in freshly isolated diabetic 
mice. After injection of P. gingivalis in control mice the number of CD 69 positive T 
cells increased 1.5 fold and B cells increased 1.8 fold from O to I day (fig 2). In diabetic 
mice after one day the increase in amount of B and T cell activation was not as 
significant as in the control group (fig 2). 
T cells give rise to specific sensitized lymphocytes which in turn have the ability to 
activate nonsensitized T cells. This activation is associated with a very important 
phenomenon know as cell recruitment. Sensitized T cells reach the site of antigen 
deposition and upon contacting the antigen; they release cytokines. These cytokines have 
the ability to make nonsensitized T cells behave as though they are sensitized ie. (release 
cytokines ). T .. cell cytokines also recruit other cells such as macrophages and PMN s 
(Trowbridge, 1997). 
These results suggest that diabetic lymphocytes might be intrinsically activated in 
vivo. This is very likely due to deregulated cytokine expression or abnormal metabolic 
products which have been found with inflammatory effects. With this ~'pre-activation", 
the~,e ly,npltocytes may become less responsive to bacterial challenge compared to 
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normal non-diabetic lymphocytes. This assumption is supported by the result from day 1 
after P.g injection Since CD 69 is an early marker for activation, which disappear 
shortly after, the result at day 3 is difficult to interpret without examining other later 
activation markers. Since the life span of T cells is long up to months or years and the 
life span of B cells is short i.e., days or weeks ( Roitt, 1996) probably a longer study can 
help to differentiate more between activated lymphocytes in diabetics and normal mice. 
Different mechanisms can be suggested for the method of activation in diabetic mice. 
To investigate the potential role of NO in diabetic mice for activation of lymphocytes, we 
injected a group of diabetic mice with P. gingivalis and by using NO inhibitor (ATM). 
Studies regarding NO and its influence on T cell activation vary and are questionable. 
Low levels of NO have been implicated in lymphocyte activation and proliferation 
(Barbul and Lazarou et al, 1990). Paradoxically, production oflarge amounts of NO by 
activated macrophages accounts for their ability to suppress T lymphocyte proliferation 
(Miller, 1995). 
Our results suggest that NO may play a role in early activation of T cells in diabetic 
mice. Inhibiting the NO by ATM decreases the amount of CD 69 positive T cells 
particularly at day 3 after P.g injection by 50% (Fig 6) a reverse effect was observed with 
B cells. Inhibiting NO by ATM increased the amount of CD 69 positive B cells in control 
and diabetic mice at both O and 3 days after injection of P.gingivalis (Fig 5 and 7). This 
suggests that NO serves as a suppressor for early B cell activation. However, further 
experiments need to be done in order to confinn these results. 
To investigate whether a diabetic environment can have an effect on rate of apoptosis, 
lymphocytes were separated from the spleen and the amount of apoptosis was detected by 
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using ELISA assay. No significant change in the apoptotic rate was observed between 
control and diabetic mice at day O (fig 11). Injection of P.gingivalis reduced the amount 
of apoptotic cells in both groups that can be related to the anti-apoptotic effect of some 
cytokines released during infection (fig 12 and 13). 
In contrast, the number of apoptotic macrophages was significantly higher in diabetic 
mice (fig 8 and 9). P.gingivalis injection slightly increased the number of apoptotic cells 
at day 3 (fig 10). The increase in macrophage apoptosis may be partially responsible for 
decreased anti-infection ability in diabetic individuals. There was no obvious difference 
in the numbers of macrophages obtained in diabetes and control mice from peritoneal 
cells. 
In summary, our studies demonstrate that diabetes could affect lymphocyte activation 
and macrophage apoptosis. Nitric oxide may play a role in CD69 expression by diabetic 
T lymphocytes and have an opposite effect on B lymphocytes. these findings support the 
hypothesis that the kinetics and magnitude of the host response in diabetic and normal 
mice are different, which leads to an altered inflammatory course during the microbial 
infection. 
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